A Phase IIIb, Open-Label Study To Evaluate The Safety And Tolerability Of Shorter Infusions Of Ocrelizumab In Patients With Primary Progressive And Relapsing Multiple Sclerosis
Phase of Trial: Phase III
Latest Information Update: 03 Dec 2019
Price : $35 *
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms SaROD
- Sponsors Genentech
- 03 Dec 2019 Last checked against ClinicalTrials.gov record.
- 18 Sep 2019 Status changed from active, no longer recruiting to completed.
- 13 Sep 2019 Results presented in the Genentech media release.